After several years of mega mergers, middle-market life sciences M&A is heating up. With big pharma/medical device continuing to struggle with declining returns on R&D and fewer large quality targets available, strategic acquirers are looking to the middle market to fill out their pipelines. Pharma services are also hot, with private equity taking note of recent rollups by leading contract research organizations and technology providers. In fact, a recent study indicates that more 25 percent of middle-market businesses will undergo a transaction in the next five years. Learn what you can be doing today to maximize the value of your pharma, biotech, med device or pharma services company in a transaction — whether the acquirer is a large strategic or a private equity fund.
In this session, Pepper partners Christopher S. Miller and Deborah L. Spranger will discuss practical tips, including:
This seminar is approved for one substantive CLE credits in Pennsylvania. Attorneys licensed in New Jersey may claim credit for this program under New Jersey's reciprocity policy.
This event is sponsored by Pepper Hamilton's Health Sciences Department, a team of 110 attorneys who collaborate across disciplines to solve complex legal challenges confronting clients throughout the health sciences spectrum.
Philadelphia Country Club
1601 Spring Mill Road
Gladwyne, PA 19035
There is no cost to attend.
For questions, contact Kim MacAlister at 215.981.4249 or firstname.lastname@example.org.